CN112063712A - Specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve - Google Patents
Specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve Download PDFInfo
- Publication number
- CN112063712A CN112063712A CN201911029832.5A CN201911029832A CN112063712A CN 112063712 A CN112063712 A CN 112063712A CN 201911029832 A CN201911029832 A CN 201911029832A CN 112063712 A CN112063712 A CN 112063712A
- Authority
- CN
- China
- Prior art keywords
- kit
- primer pair
- methylation
- specific primer
- methylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000011987 methylation Effects 0.000 title claims abstract description 49
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 49
- 108050002584 Septin 9 Proteins 0.000 title claims abstract description 33
- 238000002844 melting Methods 0.000 title abstract description 33
- 230000008018 melting Effects 0.000 title abstract description 33
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 30
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 30
- 108020004414 DNA Proteins 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 13
- 108091029523 CpG island Proteins 0.000 claims abstract description 11
- 102000053602 DNA Human genes 0.000 claims abstract description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 claims abstract description 3
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 15
- 238000013211 curve analysis Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 46
- 239000000523 sample Substances 0.000 description 36
- 239000012488 sample solution Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 239000007984 Tris EDTA buffer Substances 0.000 description 10
- 239000000975 dye Substances 0.000 description 9
- 101150042012 SEPTIN9 gene Proteins 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000005547 deoxyribonucleotide Substances 0.000 description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011880 melting curve analysis Methods 0.000 description 4
- 238000007855 methylation-specific PCR Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 2
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 2
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 2
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 description 2
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 2
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 102000046780 human SEPTIN9 Human genes 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 1
- ZPXCNXMJEZKRLU-LSJOCFKGSA-N Ala-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 ZPXCNXMJEZKRLU-LSJOCFKGSA-N 0.000 description 1
- XUCHENWTTBFODJ-FXQIFTODSA-N Ala-Met-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O XUCHENWTTBFODJ-FXQIFTODSA-N 0.000 description 1
- GKAZXNDATBWNBI-DCAQKATOSA-N Ala-Met-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N GKAZXNDATBWNBI-DCAQKATOSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- YNOCMHZSWJMGBB-GCJQMDKQSA-N Ala-Thr-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O YNOCMHZSWJMGBB-GCJQMDKQSA-N 0.000 description 1
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 1
- NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 1
- RWCLSUOSKWTXLA-FXQIFTODSA-N Arg-Asp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RWCLSUOSKWTXLA-FXQIFTODSA-N 0.000 description 1
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- VIINVRPKMUZYOI-DCAQKATOSA-N Arg-Met-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VIINVRPKMUZYOI-DCAQKATOSA-N 0.000 description 1
- GSUFZRURORXYTM-STQMWFEESA-N Arg-Phe-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 GSUFZRURORXYTM-STQMWFEESA-N 0.000 description 1
- ICRHGPYYXMWHIE-LPEHRKFASA-N Arg-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ICRHGPYYXMWHIE-LPEHRKFASA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 1
- XVAPVJNJGLWGCS-ACZMJKKPSA-N Asn-Glu-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVAPVJNJGLWGCS-ACZMJKKPSA-N 0.000 description 1
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 1
- OWUCNXMFJRFOFI-BQBZGAKWSA-N Asn-Gly-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O OWUCNXMFJRFOFI-BQBZGAKWSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- UFAQGGZUXVLONR-AVGNSLFASA-N Asp-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N)O UFAQGGZUXVLONR-AVGNSLFASA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- SARSTIZOZFBDOM-FXQIFTODSA-N Asp-Met-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O SARSTIZOZFBDOM-FXQIFTODSA-N 0.000 description 1
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 1
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- JXVFJOMFOLFPMP-KKUMJFAQSA-N Cys-Leu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JXVFJOMFOLFPMP-KKUMJFAQSA-N 0.000 description 1
- AZDQAZRURQMSQD-XPUUQOCRSA-N Cys-Val-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AZDQAZRURQMSQD-XPUUQOCRSA-N 0.000 description 1
- 108010090461 DFG peptide Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- HPCOBEHVEHWREJ-DCAQKATOSA-N Gln-Lys-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HPCOBEHVEHWREJ-DCAQKATOSA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- NHMRJKKAVMENKJ-WDCWCFNPSA-N Gln-Thr-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NHMRJKKAVMENKJ-WDCWCFNPSA-N 0.000 description 1
- ICRKQMRFXYDYMK-LAEOZQHASA-N Gln-Val-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ICRKQMRFXYDYMK-LAEOZQHASA-N 0.000 description 1
- KBKGRMNVKPSQIF-XDTLVQLUSA-N Glu-Ala-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KBKGRMNVKPSQIF-XDTLVQLUSA-N 0.000 description 1
- VTTSANCGJWLPNC-ZPFDUUQYSA-N Glu-Arg-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VTTSANCGJWLPNC-ZPFDUUQYSA-N 0.000 description 1
- AKJRHDMTEJXTPV-ACZMJKKPSA-N Glu-Asn-Ala Chemical compound C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AKJRHDMTEJXTPV-ACZMJKKPSA-N 0.000 description 1
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 1
- VAZZOGXDUQSVQF-NUMRIWBASA-N Glu-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)O VAZZOGXDUQSVQF-NUMRIWBASA-N 0.000 description 1
- GYCPQVFKCPPRQB-GUBZILKMSA-N Glu-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N GYCPQVFKCPPRQB-GUBZILKMSA-N 0.000 description 1
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 1
- PMSMKNYRZCKVMC-DRZSPHRISA-N Glu-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)O)N PMSMKNYRZCKVMC-DRZSPHRISA-N 0.000 description 1
- QJVZSVUYZFYLFQ-CIUDSAMLSA-N Glu-Pro-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O QJVZSVUYZFYLFQ-CIUDSAMLSA-N 0.000 description 1
- DXVOKNVIKORTHQ-GUBZILKMSA-N Glu-Pro-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O DXVOKNVIKORTHQ-GUBZILKMSA-N 0.000 description 1
- BIYNPVYAZOUVFQ-CIUDSAMLSA-N Glu-Pro-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O BIYNPVYAZOUVFQ-CIUDSAMLSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- GNPVTZJUUBPZKW-WDSKDSINSA-N Gly-Gln-Ser Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GNPVTZJUUBPZKW-WDSKDSINSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 1
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 1
- WZSHYFGOLPXPLL-RYUDHWBXSA-N Gly-Phe-Glu Chemical compound NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O WZSHYFGOLPXPLL-RYUDHWBXSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- ZJSMFRTVYSLKQU-DJFWLOJKSA-N His-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ZJSMFRTVYSLKQU-DJFWLOJKSA-N 0.000 description 1
- WGHJXSONOOTTCZ-JYJNAYRXSA-N His-Glu-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WGHJXSONOOTTCZ-JYJNAYRXSA-N 0.000 description 1
- VJJSDSNFXCWCEJ-DJFWLOJKSA-N His-Ile-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O VJJSDSNFXCWCEJ-DJFWLOJKSA-N 0.000 description 1
- ZFDKSLBEWYCOCS-BZSNNMDCSA-N His-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CC=CC=C1 ZFDKSLBEWYCOCS-BZSNNMDCSA-N 0.000 description 1
- PZAJPILZRFPYJJ-SRVKXCTJSA-N His-Ser-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O PZAJPILZRFPYJJ-SRVKXCTJSA-N 0.000 description 1
- RWIKBYVJQAJYDP-BJDJZHNGSA-N Ile-Ala-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RWIKBYVJQAJYDP-BJDJZHNGSA-N 0.000 description 1
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 1
- WNQKUUQIVDDAFA-ZPFDUUQYSA-N Ile-Gln-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N WNQKUUQIVDDAFA-ZPFDUUQYSA-N 0.000 description 1
- UBHUJPVCJHPSEU-GRLWGSQLSA-N Ile-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N UBHUJPVCJHPSEU-GRLWGSQLSA-N 0.000 description 1
- FUOYNOXRWPJPAN-QEWYBTABSA-N Ile-Glu-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FUOYNOXRWPJPAN-QEWYBTABSA-N 0.000 description 1
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
- CCYGNFBYUNHFSC-MGHWNKPDSA-N Ile-His-Phe Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CCYGNFBYUNHFSC-MGHWNKPDSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
- ZUPJCJINYQISSN-XUXIUFHCSA-N Ile-Met-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUPJCJINYQISSN-XUXIUFHCSA-N 0.000 description 1
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 1
- JUWJEAPUNARGCF-DCAQKATOSA-N Leu-Arg-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JUWJEAPUNARGCF-DCAQKATOSA-N 0.000 description 1
- REPPKAMYTOJTFC-DCAQKATOSA-N Leu-Arg-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O REPPKAMYTOJTFC-DCAQKATOSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 description 1
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 1
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 1
- MVHXGBZUJLWZOH-BJDJZHNGSA-N Leu-Ser-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MVHXGBZUJLWZOH-BJDJZHNGSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- PIXVFCBYEGPZPA-JYJNAYRXSA-N Lys-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N PIXVFCBYEGPZPA-JYJNAYRXSA-N 0.000 description 1
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 description 1
- HZLSUXCMSIBCRV-RVMXOQNASA-N Met-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N HZLSUXCMSIBCRV-RVMXOQNASA-N 0.000 description 1
- BEZJTLKUMFMITF-AVGNSLFASA-N Met-Lys-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCNC(N)=N BEZJTLKUMFMITF-AVGNSLFASA-N 0.000 description 1
- HSJIGJRZYUADSS-IHRRRGAJSA-N Met-Lys-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HSJIGJRZYUADSS-IHRRRGAJSA-N 0.000 description 1
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 1
- IQJMEDDVOGMTKT-SRVKXCTJSA-N Met-Val-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IQJMEDDVOGMTKT-SRVKXCTJSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- SEPNOAFMZLLCEW-UBHSHLNASA-N Phe-Ala-Val Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O SEPNOAFMZLLCEW-UBHSHLNASA-N 0.000 description 1
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- DDYIRGBOZVKRFR-AVGNSLFASA-N Phe-Asp-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N DDYIRGBOZVKRFR-AVGNSLFASA-N 0.000 description 1
- MGBRZXXGQBAULP-DRZSPHRISA-N Phe-Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MGBRZXXGQBAULP-DRZSPHRISA-N 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- WFHRXJOZEXUKLV-IRXDYDNUSA-N Phe-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 WFHRXJOZEXUKLV-IRXDYDNUSA-N 0.000 description 1
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
- ONORAGIFHNAADN-LLLHUVSDSA-N Phe-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N ONORAGIFHNAADN-LLLHUVSDSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 1
- PTLOFJZJADCNCD-DCAQKATOSA-N Pro-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 PTLOFJZJADCNCD-DCAQKATOSA-N 0.000 description 1
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 1
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 1
- WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- OOZJHTXCLJUODH-QXEWZRGKSA-N Pro-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 OOZJHTXCLJUODH-QXEWZRGKSA-N 0.000 description 1
- 102000012060 Septin 9 Human genes 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 1
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 1
- LRWBCWGEUCKDTN-BJDJZHNGSA-N Ser-Lys-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LRWBCWGEUCKDTN-BJDJZHNGSA-N 0.000 description 1
- BUYHXYIUQUBEQP-AVGNSLFASA-N Ser-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CO)N BUYHXYIUQUBEQP-AVGNSLFASA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- HEJJDUDEHLPDAW-CUJWVEQBSA-N Thr-His-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N)O HEJJDUDEHLPDAW-CUJWVEQBSA-N 0.000 description 1
- KLCCPYZXGXHAGS-QTKMDUPCSA-N Thr-His-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)O)N)O KLCCPYZXGXHAGS-QTKMDUPCSA-N 0.000 description 1
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Natural products CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- DXHHCIYKHRKBOC-BHYGNILZSA-N Trp-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O DXHHCIYKHRKBOC-BHYGNILZSA-N 0.000 description 1
- OGXQLUCMJZSJPW-LYSGOOTNSA-N Trp-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O OGXQLUCMJZSJPW-LYSGOOTNSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- LIQJSDDOULTANC-QSFUFRPTSA-N Val-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LIQJSDDOULTANC-QSFUFRPTSA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- AGKDVLSDNSTLFA-UMNHJUIQSA-N Val-Gln-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N AGKDVLSDNSTLFA-UMNHJUIQSA-N 0.000 description 1
- SZTTYWIUCGSURQ-AUTRQRHGSA-N Val-Glu-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SZTTYWIUCGSURQ-AUTRQRHGSA-N 0.000 description 1
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- MANXHLOVEUHVFD-DCAQKATOSA-N Val-His-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N MANXHLOVEUHVFD-DCAQKATOSA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 1
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 1
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- RYHUIHUOYRNNIE-NRPADANISA-N Val-Ser-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RYHUIHUOYRNNIE-NRPADANISA-N 0.000 description 1
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010066988 asparaginyl-alanyl-glycyl-alanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010025488 pinealon Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a specific primer pair and a kit for detecting septin9 gene methylation based on a high-resolution melting curve. The invention firstly protects a specific primer pair consisting of SEQ ID NO: 1 and the single-stranded DNA molecule of SEQ ID NO: 2, and 2 is shown in the specification. The invention also protects the application of the specific primer pair in the preparation of the kit. The kit has the functions of diagnosing or assisting in diagnosing colorectal cancer, detecting methylation of a promoter region of a septin9 gene and detecting methylation of a CpG island of a promoter region of a septin9 gene. The primer pair provided by the invention is used for detecting the methylation of the septin9 gene by combining methylation specificity PCR with HRM curve analysis, and has the advantages of simple and convenient operation, good specificity, high sensitivity and low cost. The invention can be used for early screening or auxiliary diagnosis of colorectal cancer patients and has good prospect in health screening and clinical auxiliary diagnosis.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a specific primer pair and a kit for detecting septin9 gene methylation based on a high-resolution melting curve.
Background
Colorectal cancer is a common malignant tumor of the digestive tract, and the incidence rate is second to gastric cancer and esophageal cancer. In the fatality rate of malignant tumors in our country, colorectal cancer patients account for the 5 th in men and the 6 th in women. The incidence rate of colorectal cancer is gradually increased in recent 20 years, more than 80% of patients in China have already developed to middle and late stages when diagnosed, the early diagnosis rate is only 10% -15%, and domestic investigation shows that the survival rate after early stage surgery is 90% -95%, and the survival rate at late stage is only 5%. The early colorectal cancer can be radically treated by the operation treatment, and the average survival time of the late colorectal cancer after the molecular targeted treatment combined with the chemoradiotherapy is still less than 30 months, so the early diagnosis of the colorectal cancer is very important and urgent.
The change of DNA methylation state is closely related to the occurrence and development of colorectal cancer. CpG islands of the septin9 gene were highly methylated in colorectal cancer patients. Therefore, CpG island methylation of septin9 gene can be used as a potential diagnostic marker of colorectal cancer. The Septin9 gene plays a role of cancer suppressor gene in colorectal cancer, and methylation can inhibit the normal expression of the gene, so that the cancer suppressor function is lost, and finally cell division and canceration are caused. Researches find that the Septin9 gene is highly expressed in tumor tissues and peripheral blood of colorectal cancer patients, is lowly expressed in healthy people or patients with other diseases, and has the highest sensitivity and specificity, thereby establishing the basic idea that the Septin9 gene expression level in blood plasma is the best candidate marker for colorectal cancer; subsequently, the Septin9 gene expression in plasma samples of colorectal cancer patients and healthy controls is analyzed through experiments, and the Septin9 gene is highly methylated in colorectal cancer tissues. The CpG island of Septin9 gene is methylated in colorectal cancer patient, while the CpG island of Septin9 gene is not methylated in normal person.
Gene methylation detection techniques can be broadly divided into two categories, site-specific methylation detection and genome-wide methylation analysis, the latter also known as methylation profiling. Methylation-specific PCR (MS-PCR) has the advantages of high sensitivity, no restriction by endonuclease, no need of special instrument, economy and practicality, and can be used for paraffin embedding samples. For methylation specific PCR, it is most important to design good quality primers. The bisulfite treatment combined sequencing method is a gold standard for DNA methylation analysis, is reliable and high in accuracy, can determine the methylation state of each CpG site in a target fragment, but needs a large amount of clone sequencing, and has a complex process.
The fluorescent quantitative method (Methylight) has the advantages of high flux and high sensitivity, and does not need operations such as electrophoresis and hybridization after PCR, thereby reducing pollution and operation errors. High-resolution melting curve analysis (HRM) is a novel molecular detection technology, is widely applied to the fields of gene mutation, gene methylation level detection, genotyping detection, HLA (human leukocyte antigen) typing and the like, has the characteristics of low cost, High flux, no pollution, quickness, simplicity and convenience in operation, good sensitivity and specificity, has the sensitivity of more than 1-5 percent, and does not need to perform subsequent operation on PCR products. The high-resolution melting technology is consistent with the principle of a common melting curve, and the combination condition of the double-stranded DNA fluorescent dye and a PCR amplification product in the temperature rising process is monitored in real time; the difference is mainly reflected in the rate of temperature rise and the dye used. It uses a new type of saturated dye (such as EVAGreen), the dye drops off when melting, the fluorescence signal is reduced, and the melting curve of the amplification product can be obtained by detecting the change of the fluorescence signal with the temperature. The dye applied by the traditional melting curve technology can inhibit PCR at high concentration, so that the sufficient concentration is difficult to achieve and the saturation combination with a PCR product is achieved, and the saturation dye applied by HRM does not influence PCR amplification in a quite large concentration range, so that the saturation combination with the PCR product can be achieved, and the DNA melting process can be reflected more accurately. The dye has stronger DNA binding capacity and very low inhibition effect, and is combined with the accurate temperature control capacity of a real-time fluorescence quantitative PCR instrument (such as Rotor-Gene Q) with a high-resolution melting analysis function. In addition, compared with the conventional melting instrument, the HRM melting instrument has higher data acquisition rate, fluorescence signal sensitivity and temperature accuracy, and ensures the consistency of the temperature among samples, thereby greatly improving the accuracy of data.
Disclosure of Invention
The invention aims to provide a specific primer pair and a kit for detecting septin9 gene methylation based on a high-resolution melting curve.
The invention firstly protects a specific primer pair consisting of SEQ ID NO: 1 and the single-stranded DNA molecule of SEQ ID NO: 2, and 2 is shown in the specification.
The function of the specific primer pair is to diagnose or assist in diagnosing the colorectal cancer.
The function of the specific primer pair is to detect methylation of a septin9 gene promoter region.
The specific primer pair has the function of detecting CpG island methylation of a promoter region of the septin9 gene.
The invention also protects the application of the specific primer pair in the preparation of the kit; the kit has the function of diagnosing or assisting in diagnosing colorectal cancer.
The invention also protects the application of the specific primer pair in the preparation of the kit; the kit has the function of detecting methylation of the promoter region of the septin9 gene.
The invention also protects the application of the specific primer pair in the preparation of the kit; the kit has the function of detecting CpG island methylation of the promoter region of the septin9 gene.
The invention also provides a kit, which comprises the specific primer pair; the kit has the function of diagnosing or assisting in diagnosing colorectal cancer.
The invention also provides a kit, which comprises the specific primer pair; the kit has the function of detecting methylation of the promoter region of the septin9 gene.
The invention also provides a reagent or a kit, which comprises the specific primer pair; the kit has the function of detecting CpG island methylation of the promoter region of the septin9 gene.
Any of the above kits further comprises a PCR amplification reagent and a fluorescent dye.
The fluorescent dye may in particular be the saturation dye EVAGreen.
The PCR amplification reagent specifically comprises: TaKaRa Ex Taq, 10 XEx Taq Buffer (Mg)2+free)、MgCl2、dNTP Mixture。
Any of the kits above further comprising reagents for performing bisulfite treatment of DNA.
Any of the above kits further comprises a carrier carrying the following detection methods:
(1) extracting the total DNA of a sample to be detected, and then carrying out bisulfite treatment;
(2) PCR amplification and high resolution melting curve analysis were performed.
The reaction procedure for PCR amplification is detailed in Table 2.
The parameter setting of the high resolution melting curve analysis may specifically be: 65 ℃ for 1s, then from 65 ℃ to 95 ℃ at a rate of 0.02 ℃/s (25 fluorescences collected per second), and finally 40 ℃ for 30 s.
Any one of the above kits further comprises a vector carrying the following criteria: the presence of a melting peak at the 87 ℃. + -. 0.5 ℃ position indicates the presence of septin9 gene methylation in the sample (candidate colorectal cancer patient), and the absence of a melting peak at the 87 ℃. + -. 0.5 ℃ position indicates the absence of septin9 gene methylation in the sample (candidate non-colorectal cancer patient).
The invention also provides a preparation method of the kit, which comprises the step of independently packaging each primer.
Any one of the above-mentioned septin9 genes is a gene encoding human septin9 protein.
The human septin9 protein is specifically shown as a sequence 4 in a sequence table.
In the human cDNA, the open reading frame of the septin9 gene is specifically shown as the 309-2048 th site in the sequence 3 of the sequence table.
The CpG island of the promoter region of the septin9 gene can be specifically nucleotides 34-204 in the sequence 3 of the sequence table.
In order to solve the defects of complex operation, pollution risk, low sensitivity and poor specificity in the existing methylation detection method, the invention provides a pair of specific primers for detecting septin9 methylation, a CG locus is added into a septin9 gene detection primer, the primers are selectively combined with a methylated sequence in a complementary manner, the PCR bias caused by the tendency of an unmethylated sequence is compensated, the sensitivity of septin9 gene detection is effectively increased, and the sensitivity of the method is better than that of methylation fluorescence quantitative PCR.
The primer pair provided by the invention is used for detecting the methylation of the septin9 gene by combining methylation specificity PCR with HRM curve analysis, and has the advantages of simple and convenient operation, good specificity, high sensitivity and low cost. The invention can be used for early screening or auxiliary diagnosis of colorectal cancer patients and has good prospect in health screening and clinical auxiliary diagnosis.
Drawings
FIG. 1 is a graph showing the change in fluorescence of HRM curve when primer pair A was used in example 3.
FIG. 2 is a peak diagram of a melting curve when the primer set A is used in example 3 (100% methylated sample).
FIG. 3 is a peak diagram of a melting curve when the primer set A is used in example 3 (75% methylated specimen).
FIG. 4 is a peak diagram of a melting curve when the primer set A is used in example 3 (50% methylated specimen).
FIG. 5 shows the melting curve peak (25% methylated specimen) when the primer set A was used in example 3.
FIG. 6 is a peak diagram of a melting curve when the primer set A is used in example 3 (10% methylated sample).
FIG. 7 is a peak diagram of a melting curve when the primer set A is used in example 3 (5% methylated sample).
FIG. 8 is a peak diagram of a melting curve when the primer set A is used in example 3 (2% methylated specimen).
FIG. 9 shows the melting curve peak (1% methylated specimen) when the primer set A was used in example 3.
FIG. 10 is a peak diagram of a melting curve when the primer set A is used in example 3 (0% methylation sample).
FIG. 11 is a peak diagram of a melting curve when the primer set A is used in example 3 (overlay of each sample).
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged. Unless otherwise specified, in the DNA molecules of the examples, A's each represent adenine deoxyribonucleotide, T's each represent thymine deoxyribonucleotide, C's each represent cytosine deoxyribonucleotide, and G's each represent guanine deoxyribonucleotide. pMD20-T vector: baozi medicine technology (Beijing) Inc., cat # 6028.
Example 1 design and preparation of primers and preparation of Standard plasmids
Design and preparation of primers
A plurality of primer pairs are designed based on the CpG island of the septin9 gene, the effect of the primer pairs is verified through a pre-experiment respectively, and 3 primer pairs are obtained through preliminary screening.
The primer pair A consists of a primer F1 and a primer R1.
F1(SEQ ID NO:1):5’-GTTAGTGCGAGATAGGGAGGTC-3’;
R1(SEQ ID NO:2):5’-CAATACAAAACTAACCGCCG-3’。
Primer pair B consists of primer F2 and primer R2.
F2:5’-AGAAATTTTAGGATTTGGGCG-3’;
R2:5’-GACGTTCTCCACCTACTTAAACG-3’。
Primer pair C consists of primer F3 and primer R3.
F3:5’-GTGTTGGGTTATAAGACGTTAGAATC-3’;
R3:5’-TAACAAAAACAATAAACACCTCGAA-3’。
Each of the above primers was synthesized separately.
Second, preparation of Standard plasmid
Preparation of Standard plasmid I (non-methylated plasmid): DNA molecules (C all represent cytosine deoxyribonucleotide) shown in a sequence 3 of a sequence table are inserted between enzyme cutting sites of pMD20-T vector Hind III and Kpn I to obtain a standard plasmid I.
Preparation of Standard plasmid II (methylated plasmid): the DNA molecule shown in the sequence 3 of the sequence table (all C in CG in three specific intervals represent 5-methylcytosine deoxyribonucleotide, the other C represent cytosine deoxyribonucleotide; the three specific intervals are 34-204 th site, 469 th site and 654 th site and 696 th site of 828 th site in the sequence 3) is inserted between Hind III and Kpn I enzyme cutting sites of pMD20-T vector to obtain the standard plasmid II.
Example 2 establishment of a method for detecting methylation by methylation specific PCR in combination with HRM Curve analysis
1. Bisulfite treatment
Mu.l of sample solution is taken and treated with bisulfite to obtain 10. mu.l of product solution, namely the template solution. The kit used for the bisulfite treatment was: EZ-96DNA Methylation-Gold MagPrep (ZYMO, cat # D5042); the operation is carried out according to the kit instructions.
2. Performing PCR amplification and high resolution melting curve analysis
The reaction system is shown in Table 1.
The amplification reaction procedure is shown in Table 2.
High-resolution melting (HRM) curve analysis is performed after amplification. Parameters for HRM curve analysis were set as: 65 ℃ for 1s, then from 65 ℃ to 95 ℃ at a rate of 0.02 ℃/s (25 fluorescences collected per second), and finally 40 ℃ for 30 s.
TABLE 1
Components | Volume of addition |
TaKaRa Ex Taq | 0.4μL |
10×Ex Taq Buffer(Mg2+free) | 3μL |
25mM MgCl2Solutions of | 3μL |
Primer solution | 2μL |
dNTP Mixture | 3μL |
Saturated dye EVAGreen | 1.5μL |
Template solution | 5μL |
DNase-free water | Make up to 30. mu.L |
TaKaRa Ex Taq: takara, cat No. RR01AM, product size 5U/. mu.l; and (3) product website: https:// www.takarabiomed.com.cn/productshow. aspx? m 20141215102854153148& productID 20141223192454673006.
10×Ex Taq Buffer(Mg2+free) and 25mM MgCl2Solution: takara, cat number 9152 AM; and (3) product website: https:// www.takarabiomed.com.cn/productshow. aspx? m-20141215102854153148&productID=20141223195903453090。
The primer solution provides effective components of a primer F and a primer R. In the primer solution, the concentration of each of the primers F and R was 10. mu.M.
The effective components provided by dNTP mix are dATP, dTTP, dCTP and dGTP. dNTP mix: biometrics (Shanghai) Inc., cat # B500056-0005; and (3) product website: https:// www.sangon.com/product detail? Code ═ B500056.
Saturated dye EVAGreen: beijing Boleidekko technology development Limited (Biotium, manufacturer U.S.); and (3) product website: http:// www.bjbiolead.com/biolead 2013-ParentList-859509/.
TABLE 2
3. Result judgment
Quality control standard: taking the methylated plasmid solution as a sample solution, sequentially performing the step 1 and the step 2, wherein the melting curve is normal, and a melting peak appears only at the position of 87 +/-0.5 ℃; the non-methylated plasmid solution is used as a sample solution to sequentially carry out the step 1 and the step 2, the melting curve is normal, and the melting peak appears only at the position of 82 +/-0.5 ℃.
And (4) judging a result standard: and (2) sequentially performing step 1 and step 2 on a sample solution (namely the solution obtained by extracting the genome DNA of the biological sample to be detected), wherein the existence of septin9 gene methylation in the sample (the sample is a candidate colorectal cancer patient) is indicated by the occurrence of a melting peak at the position of 87 +/-0.5 ℃, and the absence of septin9 gene methylation in the sample (the sample is a candidate non-colorectal cancer patient).
Example 3 sensitivity detection
The sample solution, also called 100% methylated sample, was prepared with methylated plasmid and TE buffer. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 75%) also called a 75% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and a TE buffer solution. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 50%) also called 50% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and TE buffer. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 25%) also called 25% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and TE buffer. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 10%) also called 10% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and TE buffer. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 5%) also called a 5% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and a TE buffer solution. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 2%) also called 2% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and TE buffer. A sample solution (the mass percentage of the methylated plasmids to the total plasmids is 1%) also called a 1% methylated sample is prepared by using the methylated plasmids, the unmethylated plasmids and a TE buffer solution. The sample solution, also called 0% methylated sample, was prepared with unmethylated plasmid and TE buffer. The DNA content was 100ng per 5. mu.L of the sample solution.
Detection was performed in the order of step 1 and step 2 of example 2. Three primer pairs of example 1 were used, respectively.
Methylation was detected from 2% methylated to 100% methylated samples using three primer pairs. In 1% methylated samples, only primer pair A could detect methylation, and neither primer pair B nor primer pair C could detect methylation. 0% methylated samples, no methylation was detected with all three primer pairs. That is, the sensitivity of the primer pair A for detecting methylation was 1%, the sensitivity of the primer pair B and the primer pair C for detecting methylation was 2%, and the sensitivity of the primer pair A was 2 times that of the other two primer pairs.
The change in fluorescence of the primer pair A when analyzed by HRM curve is shown in FIG. 1. The melting curve peaks when primer pairs were used for A are shown in FIGS. 2 to 11. Fig. 2 to 10 correspond in sequence to 100% methylated samples to 0% methylated samples, and fig. 11 is an overlay of fig. 2 to 10.
Example 4 reproducibility test
The sample solution was prepared with methylated plasmid, unmethylated plasmid and TE buffer. The DNA content was 100ng per 5. mu.L of the sample solution. In the sample solution 1, the methylated plasmids accounted for 10% by mass of the total plasmids. In the sample solution 2, the mass percentage of the methylated plasmids to the total plasmids was 1%.
Detection was performed in the order of step 1 and step 2 of example 2. Primer set A of example 1 was used.
20 replicates were performed. The results are shown in Table 3. The mixed template with two concentrations is repeatedly detected for 20 times, and the result can normally detect methylation, which shows that the method has good repeatability.
TABLE 3
Example 5 clinical sample testing
Paraffin sections of colorectal tissue were obtained from a hospital from 10 volunteers. Wherein clinical sample 2 and clinical sample 8 are both obtained from hospital confirmed colorectal cancer patients. The remaining 8 clinical specimens were obtained from hospital confirmed non-colorectal cancer patients.
The paraffin sections were taken and total DNA was extracted as a sample solution.
Detection was performed in the order of step 1 and step 2 of example 2. Primer set A of example 1 was used.
The results are shown in Table 4. Clinical samples 2 and 8 were able to detect Septin9 gene methylation.
TABLE 4
Clinical sample numbering | Clinical sample 1 | |
Clinical sample 3 | |
Clinical sample 5 |
Results | Non-methylated | Methylation of | Non-methylated | Non-methylated | Non-methylated |
Clinical sample numbering | |
Clinical sample 7 | |
|
|
Results | Non-methylated | Non-methylated | Methylation of | Non-methylated | Non-methylated |
SEQUENCE LISTING
<110> Beijing kang Mei Tianhong Biotech Co., Ltd
<120> specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve
<130> GNCYX192028
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 22
<212> DNA
<213> Artificial sequence
<400> 1
<210> 2
<211> 20
<212> DNA
<213> Artificial sequence
<400> 2
<210> 3
<211> 2048
<212> DNA
<213> Homo sapiens
<400> 3
ccccaggcct ggccttgaca ggcgggcgga gcagccagtg cgagacaggg aggccggtgc 60
gggtgcggga acctgatccg cccgggaggc gggggcgggg cgggggcgca gcgcgcgggg 120
aggggccggc gcccgccttc ctcccccatt cattcagctg agccaggggg cctaggggct 180
cctccggcgg ctagctctgc actgcaggag cgcgggcgcg gcgccccagc cagcgcgcag 240
ggcccgggcc ccgccggggg cgcttcctcg ccgctgccct ccgcgcgacc cgctgcccac 300
cagccatcat gtcggacccc gcggtcaacg cgcagctgga tgggatcatt tcggacttcg 360
aagccttgaa aagatctttt gaggtcgagg aggtcgagac acccaactcc accccacccc 420
ggagggtcca gactccccta ctccgagcca ctgtggccag ctccacccag aaattccagg 480
acctgggcgt gaagaactca gaaccctcgg cccgccatgt ggactcccta agccaacgct 540
cccccaaggc gtccctgcgg agggtggagc tctcgggccc caaggcggcc gagccggtgt 600
cccggcgcac tgagctgtcc attgacatct cgtccaagca ggtggagaac gccggggcca 660
tcggcccgtc ccggttcggg ctcaagaggg ccgaggtgtt gggccacaag acgccagaac 720
cggcccctcg gaggacggag atcaccatcg tcaaacccca ggagtcagcc caccggagga 780
tggagccccc tgcctccaag gtccccgagg tgcccactgc ccctgccacc gacgcagccc 840
ccaagagggt ggagatccag atgcccaagc ctgctgaggc gcccaccgcc cccagcccag 900
cccagacctt ggagaattca gagcctgccc ctgtgtctca gctgcagagc aggctggagc 960
ccaagcccca gccccctgtg gctgaggcta caccccggag ccaggaggcc actgaggcgg 1020
ctcccagctg cgttggcgac atggccgaca cccccagaga tgccgggctc aagcaggcgc 1080
ctgcatcacg gaacgagaag gccccggtgg acttcggcta cgtggggatt gactccatcc 1140
tggagcagat gcgccggaag gccatgaagc agggcttcga gttcaacatc atggtggtcg 1200
ggcagagcgg cttgggtaaa tccaccttaa tcaacaccct cttcaaatcc aaaatcagcc 1260
ggaagtcggt gcagcccacc tcagaggagc gcatccccaa gaccatcgag atcaagtcca 1320
tcacgcacga tattgaggag aaaggcgtcc ggatgaagct gacagtgatt gacacaccag 1380
ggttcgggga ccacatcaac aacgagaact gctggcagcc catcatgaag ttcatcaatg 1440
accagtacga gaaatacctg caggaggagg tcaacatcaa ccgcaagaag cgcatcccgg 1500
acacccgcgt ccactgctgc ctctacttca tccccgccac cggccactcc ctcaggcccc 1560
tggacatcga gtttatgaaa cgcctgagca aggtggtcaa catcgtccct gtcatcgcca 1620
aggcggacac actcaccctg gaggagaggg tccacttcaa acagcggatc accgcagacc 1680
tgctgtccaa cggcatcgac gtgtaccccc agaaggaatt tgatgaggac tcggaggacc 1740
ggctggtgaa cgagaagttc cgggagatga tcccatttgc tgtggtgggc agtgaccacg 1800
agtaccaggt caacggcaag aggatccttg ggaggaagac caagtggggt accatcgaag 1860
ttgaaaacac cacacactgt gagtttgcct acctgcggga ccttctcatc aggacgcaca 1920
tgcagaacat caaggacatc accagcagca tccacttcga ggcgtaccgt gtgaagcgcc 1980
tcaacgaggg cagcagcgcc atggccaacg gcatggagga gaaggagcca gaagccccgg 2040
agatgtag 2048
<210> 4
<211> 579
<212> PRT
<213> Homo sapiens
<400> 4
Met Ser Asp Pro Ala Val Asn Ala Gln Leu Asp Gly Ile Ile Ser Asp
1 5 10 15
Phe Glu Ala Leu Lys Arg Ser Phe Glu Val Glu Glu Val Glu Thr Pro
20 25 30
Asn Ser Thr Pro Pro Arg Arg Val Gln Thr Pro Leu Leu Arg Ala Thr
35 40 45
Val Ala Ser Ser Thr Gln Lys Phe Gln Asp Leu Gly Val Lys Asn Ser
50 55 60
Glu Pro Ser Ala Arg His Val Asp Ser Leu Ser Gln Arg Ser Pro Lys
65 70 75 80
Ala Ser Leu Arg Arg Val Glu Leu Ser Gly Pro Lys Ala Ala Glu Pro
85 90 95
Val Ser Arg Arg Thr Glu Leu Ser Ile Asp Ile Ser Ser Lys Gln Val
100 105 110
Glu Asn Ala Gly Ala Ile Gly Pro Ser Arg Phe Gly Leu Lys Arg Ala
115 120 125
Glu Val Leu Gly His Lys Thr Pro Glu Pro Ala Pro Arg Arg Thr Glu
130 135 140
Ile Thr Ile Val Lys Pro Gln Glu Ser Ala His Arg Arg Met Glu Pro
145 150 155 160
Pro Ala Ser Lys Val Pro Glu Val Pro Thr Ala Pro Ala Thr Asp Ala
165 170 175
Ala Pro Lys Arg Val Glu Ile Gln Met Pro Lys Pro Ala Glu Ala Pro
180 185 190
Thr Ala Pro Ser Pro Ala Gln Thr Leu Glu Asn Ser Glu Pro Ala Pro
195 200 205
Val Ser Gln Leu Gln Ser Arg Leu Glu Pro Lys Pro Gln Pro Pro Val
210 215 220
Ala Glu Ala Thr Pro Arg Ser Gln Glu Ala Thr Glu Ala Ala Pro Ser
225 230 235 240
Cys Val Gly Asp Met Ala Asp Thr Pro Arg Asp Ala Gly Leu Lys Gln
245 250 255
Ala Pro Ala Ser Arg Asn Glu Lys Ala Pro Val Asp Phe Gly Tyr Val
260 265 270
Gly Ile Asp Ser Ile Leu Glu Gln Met Arg Arg Lys Ala Met Lys Gln
275 280 285
Gly Phe Glu Phe Asn Ile Met Val Val Gly Gln Ser Gly Leu Gly Lys
290 295 300
Ser Thr Leu Ile Asn Thr Leu Phe Lys Ser Lys Ile Ser Arg Lys Ser
305 310 315 320
Val Gln Pro Thr Ser Glu Glu Arg Ile Pro Lys Thr Ile Glu Ile Lys
325 330 335
Ser Ile Thr His Asp Ile Glu Glu Lys Gly Val Arg Met Lys Leu Thr
340 345 350
Val Ile Asp Thr Pro Gly Phe Gly Asp His Ile Asn Asn Glu Asn Cys
355 360 365
Trp Gln Pro Ile Met Lys Phe Ile Asn Asp Gln Tyr Glu Lys Tyr Leu
370 375 380
Gln Glu Glu Val Asn Ile Asn Arg Lys Lys Arg Ile Pro Asp Thr Arg
385 390 395 400
Val His Cys Cys Leu Tyr Phe Ile Pro Ala Thr Gly His Ser Leu Arg
405 410 415
Pro Leu Asp Ile Glu Phe Met Lys Arg Leu Ser Lys Val Val Asn Ile
420 425 430
Val Pro Val Ile Ala Lys Ala Asp Thr Leu Thr Leu Glu Glu Arg Val
435 440 445
His Phe Lys Gln Arg Ile Thr Ala Asp Leu Leu Ser Asn Gly Ile Asp
450 455 460
Val Tyr Pro Gln Lys Glu Phe Asp Glu Asp Ser Glu Asp Arg Leu Val
465 470 475 480
Asn Glu Lys Phe Arg Glu Met Ile Pro Phe Ala Val Val Gly Ser Asp
485 490 495
His Glu Tyr Gln Val Asn Gly Lys Arg Ile Leu Gly Arg Lys Thr Lys
500 505 510
Trp Gly Thr Ile Glu Val Glu Asn Thr Thr His Cys Glu Phe Ala Tyr
515 520 525
Leu Arg Asp Leu Leu Ile Arg Thr His Met Gln Asn Ile Lys Asp Ile
530 535 540
Thr Ser Ser Ile His Phe Glu Ala Tyr Arg Val Lys Arg Leu Asn Glu
545 550 555 560
Gly Ser Ser Ala Met Ala Asn Gly Met Glu Glu Lys Glu Pro Glu Ala
565 570 575
Pro Glu Met
Claims (10)
1. A specific primer pair consisting of SEQ ID NO: 1 and the single-stranded DNA molecule of SEQ ID NO: 2, and 2 is shown in the specification.
2. The specific primer pair of claim 1, wherein: the function of the specific primer pair is to diagnose or assist in diagnosing the colorectal cancer.
3. The specific primer pair of claim 1, wherein: the function of the specific primer pair is to detect methylation of a septin9 gene promoter region.
4. The use of the specific primer pair of claim 1 in the preparation of a kit; the kit has the function of diagnosing or assisting in diagnosing colorectal cancer.
5. The use of the specific primer pair of claim 1 in the preparation of a kit; the kit has the function of detecting methylation of the promoter region of the septin9 gene.
6. The use of the specific primer pair of claim 1 in the preparation of a kit; the kit has the function of detecting CpG island methylation of the promoter region of the septin9 gene.
7. A kit comprising a specific primer pair of claim 1; the kit has the function of diagnosing or assisting in diagnosing colorectal cancer.
8. A kit comprising a specific primer pair of claim 1; the kit has the function of detecting methylation of the promoter region of the septin9 gene.
9. The kit of claim 7 or 8, wherein: the kit also has PCR amplification reagents and a fluorescent dye.
10. A method for preparing a kit according to claim 7 or 8, comprising the step of packaging each primer separately.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911029832.5A CN112063712A (en) | 2019-10-28 | 2019-10-28 | Specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911029832.5A CN112063712A (en) | 2019-10-28 | 2019-10-28 | Specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112063712A true CN112063712A (en) | 2020-12-11 |
Family
ID=73657957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911029832.5A Pending CN112063712A (en) | 2019-10-28 | 2019-10-28 | Specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112063712A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109593840A (en) * | 2017-09-29 | 2019-04-09 | 傅新晖 | Detect primer pair, kit and the method for MLH1 gene promoter methylation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106244724A (en) * | 2016-10-26 | 2016-12-21 | 北京鑫诺美迪基因检测技术有限公司 | The primer of detection septin9 gene methylation and test kit |
CN107326089A (en) * | 2017-08-16 | 2017-11-07 | 迈基诺(重庆)基因科技有限责任公司 | A kind of method and its application that Septin9 gene promoter methylations are detected based on NGS |
CN107663538A (en) * | 2005-04-15 | 2018-02-06 | Epi基因组股份公司 | Analyze the method and nucleic acid of cell proliferative disorders |
WO2018087129A1 (en) * | 2016-11-08 | 2018-05-17 | Region Nordjylland, Aalborg University Hospital | Colorectal cancer methylation markers |
WO2019045016A1 (en) * | 2017-08-31 | 2019-03-07 | 公益財団法人がん研究会 | High-sensitivity, quantitative gene examination method, primer set, and examination kit |
-
2019
- 2019-10-28 CN CN201911029832.5A patent/CN112063712A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107663538A (en) * | 2005-04-15 | 2018-02-06 | Epi基因组股份公司 | Analyze the method and nucleic acid of cell proliferative disorders |
CN106244724A (en) * | 2016-10-26 | 2016-12-21 | 北京鑫诺美迪基因检测技术有限公司 | The primer of detection septin9 gene methylation and test kit |
WO2018087129A1 (en) * | 2016-11-08 | 2018-05-17 | Region Nordjylland, Aalborg University Hospital | Colorectal cancer methylation markers |
CN107326089A (en) * | 2017-08-16 | 2017-11-07 | 迈基诺(重庆)基因科技有限责任公司 | A kind of method and its application that Septin9 gene promoter methylations are detected based on NGS |
WO2019045016A1 (en) * | 2017-08-31 | 2019-03-07 | 公益財団法人がん研究会 | High-sensitivity, quantitative gene examination method, primer set, and examination kit |
Non-Patent Citations (3)
Title |
---|
S. B. SHARIF等: "Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker", 《ONCOLOGY LETTERS》 * |
王侦等: "MS-HRM检测游离甲基化SEPT9在结直肠癌早期诊断中的应用", 《广东医学》 * |
胡笑蓉等: "一种基于HRM技术的快速DNA甲基化检测方法", 《中国卫生检验杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109593840A (en) * | 2017-09-29 | 2019-04-09 | 傅新晖 | Detect primer pair, kit and the method for MLH1 gene promoter methylation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109825586B (en) | DNA methylation qPCR kit for lung cancer detection and use method | |
CN111676292B (en) | Composition for detecting liver cancer, kit and application thereof | |
JP2022530483A (en) | Detection Technique System and Use to Concentrate Low Abundance DNA Mutations Based on nuclease Cooperative PCR Principles | |
CN109504780B (en) | DNA methylation qPCR kit for lung cancer detection and use method thereof | |
CN107447013B (en) | Method for detecting mutation sites of codons 12 and 13 of Kras gene and kit thereof | |
CN110527710B (en) | Primer, probe and kit for detecting NTRK gene fusion mutation | |
CN110438223A (en) | Detect primer, probe and its kit and detection method of Kras point mutation | |
CN112646888B (en) | Kit for detecting mammary tumor specific methylation | |
WO2015013885A1 (en) | Method for determining nucleic acid composition of nucleic acid mixture | |
CN111206100A (en) | Kit and method for detecting mutation of T790M site of EGFR gene | |
CN113621704B (en) | Reagent and kit for detecting and diagnosing liver cancer | |
CN107513577A (en) | A kind of method of efficient detection EGFRT790M mutant and probe and kit for detection | |
CN110592217A (en) | Kit for detecting KRAS gene mutation in free DNA of peripheral blood and application thereof | |
WO2018211404A1 (en) | Composite epigenetic biomarkers for accurate screening, diagnosis and prognosis of colorectal cancer | |
CN112063712A (en) | Specific primer pair and kit for detecting septin9 gene methylation based on high-resolution melting curve | |
CN109837344B (en) | Methylated EphA7 nucleotide fragment, detection method and application thereof | |
CN110373454A (en) | A kind of kit and method of joint-detection EGFR genetic mutation | |
CN109136367B (en) | Method for improving diagnosis efficiency of BRAF gene V600E mutation | |
CN110791567B (en) | Single-site DNA methylation detection kit | |
WO2009049147A2 (en) | Method of tumor screening by detection of tumour marker in low molecular weight nucleic acid from urine | |
CN113122629B (en) | Primer and probe for hairpin amplification blocking method for gene mutation detection and application thereof | |
CN110438224B (en) | Primer, kit and detection method for UGT1A1 gene polymorphism detection | |
CN112522407A (en) | Ultra-sensitive detection method for methylation detection of plasma free DNA (deoxyribonucleic acid) genes | |
CN115948561B (en) | Reagent and detection kit for esophageal squamous carcinoma diagnosis or auxiliary diagnosis and application thereof | |
CN112251514A (en) | Lung cancer-related CMTM2 gene methylation detection primer, probe, detection reagent or kit, reaction system and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201211 |
|
RJ01 | Rejection of invention patent application after publication |